Log in
Enquire now
‌

US Patent 10899761 Heterocyclic compounds and uses thereof

Patent 10899761 was granted and assigned to Plexxikon Inc. on January, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Plexxikon Inc.
Plexxikon Inc.
Current Assignee
Plexxikon Inc.
Plexxikon Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10899761
Patent Inventor Names
Songyuan Shi0
Yan Ma0
Ben Powell0
Jiazhong Zhang0
Prabha N. Ibrahim0
Wayne Spevak0
Date of Patent
January 26, 2021
Patent Application Number
16838383
Date Filed
April 2, 2020
Patent Citations
‌
US Patent 10370374 Heterocyclic compounds and uses thereof
0
Patent Citations Received
‌
US Patent 11446287 Compounds and methods for EP300 or CBP modulation and indications therefor
0
‌
US Patent 11628176 Combinational drug therapies
0
Patent Primary Examiner
‌
Charanjit Aulakh
Patent abstract

Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10899761 Heterocyclic compounds and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.